# US 2003/0069181 A1 · Alternative splice forms of proteins as basis for multiple therapeutic modalities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069181 A1
- Document ID: US20030069181A1
- Status: Published application
- Kind: A1
- Application number: 10/156,932
- Filed: 2002-05-28
- Published: 2003-04-10
- Earliest claimed: 2001-05-25
- Assignees: Thomas Jefferson University
- Inventors: Albert J. Wong
- Web page: https://patentgrep.com/patent/US20030069181A1

## CPC

- C07K 14/52: Cytokines; Lymphokines; Interferons
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Peptides or antibodies derived from alternative splice forms of proteins associated with a disease or physiologic condition are used as therapeutic or prophylactic agents. Peptides and antibodies derived from alternative splice forms of the vascular endothelial growth factor (VEGF) family of proteins are particularly useful in preventing or delaying the onset of tumors and inducing tumor regression.

## Claims

### Claim 1

A peptide comprising an amino acid sequence unique to an alternative splice form.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide is from 4 to 50 amino acids in length.

### Claim 3 (depends on 2)

The peptide of claim 2, wherein the peptide is from 7 to 15 amino acids in length.

### Claim 4 (depends on 2)

The peptide of claim 2, wherein the peptide is 8 or 9 amino acids in length.

### Claim 5 (depends on 1)

The peptide of claim 1, wherein the peptide contains at least one normal amino acid sequence of 7 contiguous amino acids or less.

### Claim 6 (depends on 5)

The peptide of claim 5, wherein the peptide contains at least one normal amino acid sequence of 6, 5, 4, 3, 2 or 1 contiguous amino acids.

### Claim 7 (depends on 5)

The peptide of claim 5, wherein the peptide contains at least one normal amino acid sequence of 5 or 6 contiguous amino acids.

### Claim 8 (depends on 5)

The peptide of claim 5, wherein the peptide contains a splice junction, a first normal amino acid sequence of 7 contiguous amino acids or less and a second normal amino acid sequence of 7 contiguous amino acids or less, wherein the first and second normal amino acid sequences flank the alternative splice junction.

### Claim 9 (depends on 8)

The peptide of claim 8, wherein the first normal amino acid sequence has 6, 5, 4, 3, 2 or 1 contiguous amino acids and the second normal amino acid sequence has 6, 5, 4, 3, 2 or 1 contiguous amino acids.

### Claim 10 (depends on 8)

The peptide of claim 8, wherein the first and second normal amino acid sequences each have 3 or 4 contiguous amino acids.

### Claim 11 (depends on 1)

The peptide of claim 1, wherein the peptide contains at least one modification for coupling the peptide to a polyvalent platform or to another protein.

### Claim 12 (depends on 11)

The peptide of claim 11, wherein the modification comprises additional amino acids added to the C- or N-terminus of the peptide.

### Claim 13 (depends on 12)

The peptide of claim 12, wherein the amino acids added to the C- or N-terminus of the peptide are selected from the group consisting of tyrosine, cysteine, lysine, glutamic acid and aspartic acid.

### Claim 14 (depends on 13)

The peptide of claim 13, wherein the amino acid added to the C- or N-terminus of the peptide is cysteine.

### Claim 15 (depends on 11)

The peptide of claim 11, wherein the modification is selected from the group consisting of introduction of coupling sites by terminal-NH2 acylation; thioglycolic acid amidation; terminal-carboxy amidation; and biotinylation.

### Claim 16 (depends on 1)

The peptide of claim 1, which contains at least one D-amino acid.

### Claim 17 (depends on 1)

The peptide of claim 1, selected from the group consisting of SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 77; and SEQ ID NO: 79.

### Claim 18 (depends on 1)

A multimer comprising two or more peptides of claim 1.

### Claim 19 (depends on 18)

The multimer of claim 18, wherein the multimer is a homomultimer.

### Claim 20 (depends on 19)

The multimer of claim 19 which is selected from the group consisting of a dimer; trimer; tetramer; pentamer; and hexamer.

### Claim 21 (depends on 20)

The multimer of claim 20, wherein the multimer is a dimer.

### Claim 22 (depends on 21)

The dimer of claim 21 comprising two peptides of SEQ ID NO: 81.

### Claim 23 (depends on 18)

The multimer of claim 18, wherein the multimer is a heteromultimer.

### Claim 24 (depends on 23)

The multimer of claim 23 which is selected from the group consisting of a dimer; trimer; tetramer; pentamer; and hexamer.

### Claim 25

A method of identifying immunogenic peptides for treating a subject who has, or is at risk for having, a disease or condition in which diseased or abnormal cells produce at least one alternative splice form, which alternative splice form is substantially absent from normal cells, comprising the steps of:
1) identifying at least one mRNA which encodes for the at least one alternative splice form;
2) determining at least a partial amino acid sequence of the at least one alternative splice form; and
3) generating at least one peptide comprising an amino acid sequence which is unique to the alternative splice form.

### Claim 26 (depends on 1)

A method of treating a subject who has, or is at risk for having, a disease or condition in which diseased or abnormal cells produce at least one alternative splice form, which alternative splice form is substantially absent from normal cells, comprising administering an effective amount of at least one peptide of claim 1 to the subject such that an immune response is generated against the diseased or abnormal cells.

### Claim 27 (depends on 26)

The method of claim 26, wherein the immune response is an MHC HLA-class I or class II restricted cytotoxic T lymphocyte response, or an antibody response.

### Claim 28 (depends on 27)

The method of claim 27, wherein the cytotoxic T lymphocyte response is a CD8+ T lymphocyte response wherein CD8+, MHC class I-restricted T lymphocytes are activated.

### Claim 29 (depends on 27)

The method of claim 27, wherein the cytotoxic T lymphocyte response is a CD4+ T lymphocyte response wherein CD4+, MHC class II-restricted T lymphocytes are activated.

### Claim 30 (depends on 26)

The method of claim 26, wherein the subject is a human being.

### Claim 31 (depends on 26)

The method of claim 26, wherein the at least one peptide is selected from the group consisting of SEQ ID NO: 3; SEQ ID NO: 5; SEQ ID NO: 8; SEQ ID NO: 10; SEQ ID NO: 12; SEQ ID NO: 26; SEQ ID NO: 29; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 38; SEQ ID NO: 39; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 77; and SEQ ID NO: 79.

### Claim 32 (depends on 26)

The method of claim 26, wherein the immune response generated against the diseased or abnormal cells is enhanced by modifying the peptide to prior to administering the peptide to the subject.

### Claim 33 (depends on 32)

The method of claim 32, wherein the peptide is modified by increasing the hydrophobicity of the peptide N-terminus.

### Claim 34 (depends on 32)

The method of claim 32, wherein the peptide is modified with at least one amino acid insertion, deletion, or substitution which increases binding affinity of the peptide to an MHC molecule.

### Claim 35 (depends on 32)

The method of claim 32, wherein the stability of the peptide is increased by modifying the peptide prior to administering the peptide to the subject.

### Claim 36 (depends on 35)

The method of claim 35, wherein the peptide is modified by capping the peptide with a D-amino acid, replacing at least one L-amino acid of the peptide with a D-amino acid, or reversing the amino acid sequence of the peptide and replacing at least one L-amino acid with a D-amino acid.

### Claim 37 (depends on 26)

The method of claim 26, wherein two or more peptides are administered to the subject.

### Claim 38 (depends on 37)

The method of claim 37, wherein the two or more peptides comprise a multimer.

### Claim 39 (depends on 38)

The method of claim 38, wherein the multimer is a homomultimer.

### Claim 40 (depends on 39)

The method of claim 39, wherein the multimer is selected from the group consisting of a dimer; trimer; tetramer; pentamer; and hexamer.

### Claim 41 (depends on 40)

The method of claim 40, wherein the multimer is a dimer.

### Claim 42 (depends on 41)

The method of claim 41 comprising two peptides of SEQ ID NO: 81.

### Claim 43 (depends on 38)

The method of claim 38, wherein the multimer is a heteromultimer.

### Claim 44 (depends on 43)

The method of claim 43, wherein the multimer is selected from the group consisting of a dimer; trimer; tetramer; pentamer; and hexamer.

### Claim 45 (depends on 37)

The method of claim 37, wherein the two or more peptides comprise an admixture.

### Claim 46 (depends on 37)

The method of claim 37, wherein the two or more peptides comprise overlapping epitopes from one or more alternative splice forms.

### Claim 47 (depends on 26)

The method of claim 26, wherein the at least one peptide is administered to the subject in combination with peptides that present T-helper cell epitopes.

### Claim 48 (depends on 26)

The method of claim 26, wherein the at least one peptide is administered to the subject in combination with at least one component that primes cytotoxic T lymphocytes.

### Claim 49 (depends on 48)

The method of claim 48, wherein the at least one component that primes cytotoxic T lymphocytes comprises tripalmitoyl-S-glycerylcysteinly-seryl-serine (P3CSS).

### Claim 50 (depends on 26)

The method of claim 26, wherein the effective amount is about 1 microgram to about 2,000 mg of the at least one peptide per 70 kg of subject.

### Claim 51 (depends on 26)

The method of claim 26, wherein the effective amount is about 1 microgram to about 500 mg of the at least one peptide per 70 kg of subject.

### Claim 52 (depends on 26)

The method of claim 26, wherein the effective amount is about 10 micrograms to about 200 mg of the at least one peptide per 70 kg of subject.

### Claim 53 (depends on 26)

The method of claim 26, wherein the effective amount is about 50 micrograms to about 100 mg of the at least one peptide per 70 kg of subject.

### Claim 54 (depends on 26)

The method of claim 26, wherein the effective amount of the at least one peptide is administered in a single dose.

### Claim 55 (depends on 26)

The method of claim 26, wherein the effective amount of the at least one peptide is administered in multiple doses.

### Claim 56 (depends on 26)

The method of claim 26, wherein the effective amount of the at least one peptide is administered enterally.

### Claim 57 (depends on 56)

The method of claim 56, wherein the enteral route of administration is selected from the group consisting of oral; rectal; and intranasal.

### Claim 58 (depends on 26)

The method of claim 26, wherein the effective amount of the at least one peptide is administered parenterally.

### Claim 59 (depends on 58)

The method of claim 58, wherein the parenteral route of administration is selected from the group consisting of intravenous; intramuscular; intraarterial; intraperitoneal; intravaginal; intravesical; intradermal; intrapulmonary; inhalation; topical; subcutaneous; and instillation into the body.

### Claim 60 (depends on 26)

The method of claim 26, wherein the at least one peptide is administered to a subject in combination with a carrier or adjuvant.

### Claim 61 (depends on 60)

The method of claim 60, wherein the carrier is selected from the group consisting of keyhole limpet hemocyanin; thyroglobulin; albumins; tetanus toxoid; and polyamino acids.

### Claim 62 (depends on 60)

The method of claim 60, wherein the adjuvant is selected from the group consisting of complete Freund's adjuvant; incomplete Freund's adjuvant; aluminum phosphate; aluminum hydroxide; polylecithins; emulsified oils; and alum.

### Claim 63 (depends on 26)

The method of claim 26, wherein the at least one peptide is administered to a subject in combination with an immunostimulatory compound.

### Claim 64 (depends on 63)

The method of claim 63, wherein the immunostimulatory compound is selected from the group consisting of cytokines and haptens.

### Claim 65 (depends on 64)

The method of claim 64, where the cytokines are selected from the group consisting of GM-CSF; IL-12; IL-2; IL-4; IL-1 alpha; and IL-18.

### Claim 66 (depends on 26)

The method of claim 26, wherein the effective amount of the at least one peptide is administered to a subject by expression of at least one nucleic acid sequence encoding the at least one peptide in cells of the subject

### Claim 67 (depends on 66)

The method of claim 66, wherein cells of the subject are infected with an attenuated viral host comprising the at least one nucleic acid.

### Claim 68 (depends on 67)

The method of claim 67, wherein the attenuated viral host is vaccinia virus.

### Claim 69 (depends on 66)

The method of claim 66, wherein a bacterial host comprising the at least one nucleic acid is introduced into a subject.

### Claim 70 (depends on 69)

The method of claim 69, wherein the bacterial host is selected from the group consisting of BCG; Salmonella typhi; and Listeria monocytogenes.

### Claim 71 (depends on 66)

The method of claim 66, wherein a yeast host comprising the at least one nucleic acid is introduced into a subject.

### Claim 72 (depends on 71)

The method of claim 71, wherein the yeast host is Saccharomyces cerevisiae or Schizosaccharomyces pombe.

### Claim 73 (depends on 26)

The method of claim 26, wherein the disease or condition is selected from the group consisting of stress; cancer; diseases or conditions of the immune system; metabolic disorders; connective tissue disorders; disorders of the arteries; inherited red cell membrane disorders; thyroid hormone repression; endometrial hyperplasia; Alzheimer's disease; and alcoholism.

### Claim 74 (depends on 73)

The method of claim 73, wherein the cancer is selected from the group consisting of acute promyelocytic leukemia; acute lymphoblastic leukemia; myeloblastic leukemia; uterine cancer; thyroid cancer; gastrointestinal cancer; dysplastic and neoplastic cervical epithelium; melanoma; endometrial cancer; teratocarcinoma; colon cancer; desmoplastic round cell tumors; gastric cancer; breast cancer, ovarian cancer, prostate cancer, lung cancer, skin cancer, lymphoma, bladder cancer, and pancreatic cancer.

### Claim 75 (depends on 26)

The method of claim 26, wherein the disease or disorder is selected from the group consisting of allergic response; x-linked agammaglobulinemia; immunity/inflammation; systemic lupus erythematosus; Goodpasture disease; phenylketonuria; non-insulin dependent diabetes; osteogenesis imperfecta; atherosclerosis; and hereditary elliptocytosis.

### Claim 76 (depends on 26)

The method of claim 26, wherein the alternative splice form is produced from the CD44 gene; the estrogen receptor gene; or the FHIT gene.

### Claim 77 (depends on 26)

The method of claim 26, wherein administering the at least one peptide to a subject comprises the steps of:
1) removing immune system effector cells from a subject;
2) maintaining the immune system effector cells in culture outside the body of the subject;
3) optionally enriching the immune system effector cells for a particular immune system effector cell type;
4) treating the cultured immune system effector cells with the at least one peptide;
5) optionally examining a portion of the treated immune system effector cells to confirm the presence of the at least one peptide within the cells and
6) reintroducing the treated immune system effector cells into the subject.

### Claim 78 (depends on 77)

The method of claim 77, wherein the immune system effector cells are selected from the group consisting of dendritic cells; lymphokine-activated killer cells; natural killer cells; T-cells; macrophages; and combinations thereof.

### Claim 79 (depends on 77)

The method of claim 77, wherein treatment of the immune system effector cells with the at least one peptide comprises direct exposure of the cells to the at least one peptide.

### Claim 80 (depends on 77)

The method of claim 77, wherein treatment of the immune system effector cells with the at least one peptide comprises introduction of at least one nucleic acid encoding the at least one peptide into the cells.

### Claim 81 (depends on 77)

The method of claim 77, wherein the treated immune system effector cells are reintroduced into the subject by intravenous infusion or direct injection into the bone marrow.

### Claim 82 (depends on 77)

The method of claim 77, wherein about 105 to about 108 treated immune system effector cells per kilogram of subject body weight are reintroduced into the subject.

### Claim 83 (depends on 1)

A method of preventing or delaying the onset of tumor development in a subject at risk for having a tumor in which tumor cells produce at least one alternative splice form, which alternative splice form is substantially absent from non-tumor cells, comprising administering to a subject an effective amount of at least one peptide of claim 1, such that an immune response is generated against the tumor cells.

### Claim 84 (depends on 83)

The method of claim 83, wherein the tumor derives from a cancer selected from the group consisting of a uterine cancer; thyroid cancer; gastrointestinal cancer; dysplastic and neoplastic cervical epithelium; melanoma; endometrial cancer; teratocarcinoma; colon cancer; desmoplastic round cell tumors; gastric cancer; breast cancer, ovarian cancer, prostate cancer, lung cancer, skin cancer, lymphoma, bladder cancer, and pancreatic cancer.

### Claim 85 (depends on 83)

The method of claim 83, wherein the subject is a human being.

### Claim 86 (depends on 83)

The method of claim 83, wherein two or more peptides are administered to the subject.

### Claim 87 (depends on 86)

The method of claim 86, wherein the two or more peptides comprise a multimer.

### Claim 88 (depends on 87)

The method of claim 87, wherein the multimer is selected from the group consisting of a dimer; trimer; tetramer; pentamer; and hexamer.

### Claim 89 (depends on 87)

The method of claim 87, wherein the multimer is a dimer and comprises two peptides of SEQ ID NO: 81.

### Claim 90 (depends on 86)

The method of claim 86, wherein the two or more peptides comprise an admixture.

### Claim 91 (depends on 83)

The method of claim 83, wherein the at least one peptide is selected from the group consisting of SEQ ID NO: 8; SEQ ID NO: 10; SEQ ID NO: 26; SEQ ID NO: 29; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 77; and SEQ ID NO: 79.

### Claim 92 (depends on 1)

A method of regressing a tumor in a subject having a tumor in which tumor cells produce at least one alternative splice form, which alternative splice form is substantially absent from non-tumor cells, comprising administering to a subject an effective amount of at least one peptide of claim 1, such that an immune response is generated against the tumor cells.

### Claim 93 (depends on 92)

The method of claim 92, wherein the tumor derives from a cancer selected from the group consisting of a uterine cancer; thyroid cancer; gastrointestinal cancer; dysplastic and neoplastic cervical epithelium; melanoma; endometrial cancer; teratocarcinoma; colon cancer; desmoplastic round cell tumors; gastric cancer; breast cancer, ovarian cancer, prostate cancer, lung cancer, skin cancer, lymphoma, bladder cancer, and pancreatic cancer.

### Claim 94 (depends on 92)

The method of claim 92, wherein the subject is a human being.

### Claim 95 (depends on 88)

The method of claim 88, wherein two or more peptides are administered to the subject.

### Claim 96 (depends on 95)

The method of claim 95, wherein the two or more peptides comprise a multimer.

### Claim 97 (depends on 96)

The method of claim 96, wherein the multimer is selected from the group consisting of a dimer; trimer; tetramer; pentamer; and hexamer.

### Claim 98 (depends on 97)

The method of claim 97, wherein the multimer is a dimer and comprises two peptides of SEQ ID NO: 81.

### Claim 99 (depends on 95)

The method of claim 95, wherein the two or more peptides comprise an admixture.

### Claim 100 (depends on 92)

The method of claim 92, wherein the at least one peptide is selected from the group consisting of SEQ ID NO: 8; SEQ ID NO: 10; SEQ ID NO: 26; SEQ ID NO: 29; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 77; and SEQ ID NO: 79.

### Claim 101 (depends on 1)

A method for identifying peptides which induce MHC-restricted cytotoxic T lymphocyte responses in a subject, comprising the steps of:
1) obtaining peripheral blood lymphocytes;
2) exposing the peripheral blood lymphocytes to at least one peptide of claim 1 such that the peripheral blood lymphocytes are stimulated;
3) incubating the stimulated peripheral blood lymphocytes with target cells that either endogenously synthesize the alternative splice form from which the peptide is derived or are pulsed with the peptide; and
4) detecting lysis of the target cells.

### Claim 102 (depends on 101)

The method of claim 101, wherein the target cells are autologously labeled and the detection of target cell lysis comprises measuring release of the autologous label from the lysed target cells.

### Claim 103 (depends on 101)

The method of claim 101, wherein the detection of target cell lysis comprises detection of at least one cytokine released from activated peripheral blood lymphocytes upon lysis of the target cells.

### Claim 104 (depends on 102)

The method of claim 102, wherein the at least one cytokine is interferon-gamma.

### Claim 105

An antibody or antibody fragment that binds to specific epitopes on a peptide selected from the group consisting of SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 77; and SEQ ID NO: 79.

### Claim 106 (depends on 105)

The antibody of claim 105 which is humanized.

### Claim 107 (depends on 105)

The antibody of claim 105 which is a polyclonal antibody.

### Claim 108 (depends on 105)

The antibody of claim 105 which is a monoclonal antibody.

### Claim 109 (depends on 108)

A hybridoma producing the monoclonal antibody of claim 108.

### Claim 110

A method of treating a subject having, or at risk for having, a disease or condition in which diseased or abnormal cells produce at least one alternative splice form, which alternative splice form is substantially absent from normal cells, comprising administering to a subject an effective amount of at least one antibody specific to an amino acid sequence unique to the alternative splice form, such that one or more clinical symptoms in the subject are ameliorated or the number of diseased or abnormal cells in the subject is reduced.

### Claim 111 (depends on 110)

The method of claim 110, wherein the at least one antibody is a monoclonal antibody.

### Claim 112 (depends on 110)

The method of claim 110, wherein the at least one antibody is humanized.

### Claim 113 (depends on 111)

The method of claim 111, wherein the monoclonal antibody binds to specific epitopes on a peptide selected from the group consisting of SEQ ID NO: 3; SEQ ID NO: 5; SEQ ID NO: 8; SEQ ID NO: 10; SEQ ID NO: 12; SEQ ID NO: 26; SEQ ID NO: 29; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 38; SEQ ID NO: 39; SEQ ID NO: 73; SEQ ID NO: 75; SEQ ID NO: 77; and SEQ ID NO: 79.

### Claim 114 (depends on 110)

The method of claim 110, wherein the effective amount is about 0.1 mg/kg to about 100 mg/kg of body weight.

### Claim 115 (depends on 110)

The method of claim 110, wherein the effective amount is about 50 mg/kg to about 100 mg/kg of body weight.

### Claim 116 (depends on 110)

The method of claim 110, wherein the effective amount is about 10 mg/kg to about 20 mg/kg of body weight.

### Claim 117 (depends on 1)

A pharmaceutical composition comprising at least one peptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 118 (depends on 117)

The pharmaceutical composition of claim 117 which is encapsulated in a liposome.
